Canonica Giorgio Walter, Blasi Francesco, Paggiaro Pierluigi, Senna Gianenrico, Passalacqua Giovanni, Spanevello Antonio, Aliberti Stefano, Bagnasco Diego, Bonavia Marco, Bonini Matteo, Brussino Luisa, Bucca Caterina, Caiaffa Maria F, Calabrese Cecilia, Camiciottoli Gianna, Caminati Marco, Carpagnano Giovanna E, Caruso Cristiano, Centanni Stefano, Conte Maria E, Corsico Angelo G, Cosmi Lorenzo, Costantino Maria T, Crimi Nunzio, D'Alò Simona, D'Amato Maria, Del Giacco Stefano, Farsi Alessandro, Favero Elisabetta, Foschino Barbaro Maria P, Guarnieri Gabriella, Guida Giuseppe, Latorre Manuela, Lo Cicero Salvatore, Lombardi Carlo, Macchia Luigi, Mazza Francesco, Menzella Francesco, Milanese Manlio, Montagni Marcello, Montuschi Paolo, Nucera Eleonora, Parente Roberta, Patella Vincenzo, Pelaia Girolamo, Pini Laura, Puggioni Francesca, Ricciardi Luisa, Ricciardolo Fabio L M, Richeldi Luca, Ridolo Erminia, Rolla Giovanni, Santus Pierachille, Scichilone Nicola, Spadaro Giuseppe, Vianello Andrea, Viviano Vittorio, Yacoub Mona R, Zappa Maria C, Heffler Enrico
Personalized Medicine, Asthma & Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, MI, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy.
World Allergy Organ J. 2020 Sep 20;13(10):100464. doi: 10.1016/j.waojou.2020.100464. eCollection 2020 Oct.
According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.
根据来自多个国家和国际登记处的数据，包括意大利严重哮喘网络（SANI），并考虑到频繁或常规使用口服糖皮质激素对重度哮喘患者生活质量（QoL）以及糖皮质激素相关疾病管理成本的强烈影响，在重度哮喘管理中，口服糖皮质激素减量直至停用应被视为主要目标。新型生物制剂已清楚表明这种效果是可能的，同时可降低急性加重率并控制症状。因此，在尚未探索目前大部分重度哮喘患者可用的所有替代方案之前，没有理由如此频繁地使用口服糖皮质激素。
